Kaya Miah

Research Interests

• Survival analysis
• Clinical trials
• Multi-state models
• High-dimensional biomarker studies

Education and Background

• Research visits at Leiden University Medical Center (LUMC), Netherlands (in 2023/2024)
• PhD Candidate at DKFZ/Biostatistics since September 2021
• Research Associate at DKFZ/Biostatistics since September 2019
• M. Sc. in Statistics/Biometrics, Dortmund University (2019)
• Exchange at School of Mathematics and Statistics, University of Sheffield, England (2017-2018)
• B. Sc. in Statistics/Theoretical Medicine, Dortmund University (2016)

Selected Publications

Miah, K., Goeman, J. J., Putter, H., Kopp-Schneider, A., and Benner, A. (2024). Variable selection via fused sparse-group lasso penalized multi-state models incorporating molecular data. arXiv preprint, https://arxiv.org/abs/2411.17394.

Mai, E. K., Goldschmidt, H., Miah, K. et al. (2024). Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): Results from a randomised, phase 3 trial. The Lancet Haematology, 11(2), e101–e113.

Giesen, N., Chatterjee, M., Scheid, C., Poos, A. M., Besemer, B., Miah, K. et al. (2023). A phase II clinical trial of combined BRAF/MEK inhibition for BRAFV600E-mutated multiple myeloma. Blood, 41(14), 1685-1690.

Mai, E. K., Huhn, S., Miah, K. et al. (2023). Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma. Blood Cancer Journal, 13(1), 1-9.

Mai, E. K., Miah, K. et al. (2020). Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age. Leukemia 35(3), 809-822.

Salwender, H., Elmaagacli, A., Merz, M., Miah, K. et al. (2021). Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial. Leukemia 35(10), 3007–3011.